Depression is a very costly chronic disease. An important cost driver is treatment failure caused by patient … medication switching contribute to the high cost of treatment. With the epidemiological data for depression demonstrating a rise … the treatment of depression. …

depression, the evidence for fluoxetine and for the selective serotonin reuptake inhibitors in general suggest at best a modest …Fluoxetine continues to be remarkably successful; greater volumes of this drug are sold than for any other … fluoxetine, and highlight the response of the sponsor in the development of subsequent drugs for CNS disorders. …

DRSP/EE dominated both sertraline and paroxetine, but not fluoxetine. The estimated ICER of initiating treatment with …, sertraline, paroxetine and drospirenone plus ethinyl estradiol (DRSP/EE). Abstract: Methods: A decision-analytic model was used …: Objective: To evaluate the cost effectiveness of the four medications with a US FDA-approved indication for PMDD: fluoxetine …

. Mirtazapine improved quality of life to a similar extent to fluoxetine, citalopram and paroxetine in unpublished studies of 6 and …-effective alternative to amitriptyline and fluoxetine for the treatment of depression. Mirtazapine also has similar effects to SSRIs on … serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs) on the basis of mean depression rating scale scores. Data from …

onset of therapeutic effect than citalopram. It has also been shown to lead to improvements in measures of QOL. Escitalopram … had lower estimated drug acquisition costs than venlafaxine XR. Conclusion: Escitalopram, the S-enantiomer of RS-citalopram … analyses from Western Europe suggest that it may be a cost-effective alternative to generic citalopram, generic fluoxetine and …

depressive episode were randomised to receive sertraline (50 to 150 mg/day; n = 122) or fluoxetine (20 to 60 mg/day; n = 120 … receiving sertraline, 115 receiving fluoxetine) were included in an intention-to-treat analysis assessed up to the last visit …). Assessments, including clinical evaluation [Montgomery-Asberg Depression Rating Scale (MADRS), Clinical Global Impressions (CGI …

approved for the treatment of major depressive disorder (MDD). The allosteric SSRI escitalopram has been shown to be at least …, escitalopram has been shown to be cost saving compared with venlafaxine. Objective: To evaluate the cost effectiveness of … escitalopram versus duloxetine in the treatment of MDD, and to identify key cost drivers. Methods: The pharmacoeconomic evaluation …

Aim: To assess the relative cost effectiveness of escitalopram compared with venlafaxine XR in patients with major … clinical trial and examined the costs and quality of life of 251 patients taking escitalopram versus venlafaxine. Outpatients … fulfilling criteria for MDD were randomised to receive oral escitalopram 10-20 mg/day or venlafaxine 75-150 mg/day for 8 weeks …

Manual of Mental Disorders, third and fourth editions (DSM-III/IV), with moderate-to-severe disease (Hamilton Depression … Rating Scale [HAMD] >=15 or Montgomery-Asberg Depression Rating Scale [MADRS] >=18), without co-morbidities or co …

major depression in the UK NHS. Design, patients and interventions: A decision-tree model for the treatment of major … depression was constructed by interviewing UK GPs and psychiatrists (as part of a Delphi panel). An important part of the tree … (serotonin and noradrenaline reuptake inhibitors [SNRIs; venlafaxine], selective serotonin reuptake inhibitors [SSRIs; fluoxetine …